🇺🇸 FDA

Intelligence · Patent portfolio

Arrowhead Pharmaceuticals Ireland Patents

Full USPTO pharma patent portfolio for Arrowhead Pharmaceuticals Ireland — grant dates, expiration, and drug cross-links.

Patents
126
Expiring ≤24m
0

Quick answer

Arrowhead Pharmaceuticals Ireland has 126 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Page 1 of 3

  1. US 12378558

    RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12365897

    RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12365899

    RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12221610

    RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12188017

    Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12173086

    Alpha-v beta-6 integrin ligands and uses thereof

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12116573

    Targeting ligands for therapeutic compounds

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12110492

    RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12091661

    Organic compositions to treat HSF1-related diseases

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12065458

    Trialkyne linking agents and methods of use

    Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12054718

    RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11920134

    Compositions and methods for inhibiting expression of RRM2 genes

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11912997

    RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11884920

    Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11845937

    RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11840688

    Compositions and methods for inhibiting gene expression of Hif2alpha

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11629349

    RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use

    Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11597701

    Integrin ligands and uses thereof

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11590156

    RNAi agents for hepatitis B virus infection

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11549112

    RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11534453

    RNAi therapy for hepatitis B virus infection

    Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11517584

    RNAi agents for Hepatitis B virus infection

    Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11492624

    RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1

    Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11384355

    Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11261444

    Organic compositions to treat EPAS1-related diseases

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11214802

    RNAi agents for inhibiting expression of alpha-ENaC and methods of use

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11214801

    RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11208662

    RNAi inhibition of alpha-ENaC expression

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11203756

    Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11180529

    Alpha-v beta-6 integrin ligands and uses thereof

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11174481

    Targeting ligands

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11091761

    Organic compositions to treat HSF1-related diseases

    Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11078227

    5′-cyclo-phosphonate modified nucleotides

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11066667

    Organic compositions to treat APOC3-related diseases

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10995335

    RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10927373

    Compositions and methods for inhibiting gene expression of Hif2alpha

    Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10858658

    Compositions and methods for inhibiting gene expression of factor XII

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10806750

    RNAi therapy for hepatitis B virus infection

    Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10780108

    RNAi agents for Hepatitis B virus infection

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10619160

    Compositions and methods for inhibiting expression of RRM2 genes

    Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10597657

    RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10590416

    RNAi agents for inhibiting expression of alpha-ENaC and methods of use

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10550391

    Organic compositions to treat beta-ENaC-related diseases

    Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10544418

    RNAi inhibition of alpha-ENaC expression

    Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10538765

    Organic compositions to treat EPAS1-related diseases

    Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10450565

    Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

    Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10329563

    Organic compositions to treat HSF1-related diseases

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10316316

    Compositions for targeted delivery of siRNA

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Arrowhead Pharmaceuticals Ireland have?

126 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Arrowhead Pharmaceuticals Ireland patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.